Previous studies demonstrated that the anticancer efficacy of CDK7 inhibitors was associated with CDK7-dependent transcriptional addiction in small cell lung cancer and ovarian cancer20,22 and super-enhancer-associated genes in neuroblastoma and oesophageal squamous cell carcinoma19,23. This evidence concerns the gene CDK7 and small cell lung carcinoma.